System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maud Toulmonde is an expert in Oncology at Institut Bergonié (France). As of October 2026, ScienceLeadR ranks Maud Toulmonde in the top 1% of experts worldwide for Sarcoma. Maud Toulmonde has authored 242 publications, the most recent in 2026, and is an investigator in 39 clinical trials, 10 of them ongoing. SLR score: 1,294 (community average: 125). How the SLR is computed.

LeadR Profile

Maud Toulmonde Institut Bergonié France
1 294 ScienceLeadR Reputation 1294

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Biochemistry - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2026
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 242

Citations

Citations: 11 322 1st author: 34 Last author: 11 Unique author: 1

Main journals

Ann Oncol 51
J Clin Oncol 40
Eur J Cancer 23
Lancet Oncol 11
ESMO Open 9

Best Journals

Ann Oncol 28
J Clin Oncol 13
Lancet Oncol 11

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Insights into rhabdomyosarcoma in the adolescent and young adult population: a comprehensive clinical study from the French Society of Pediatric Oncology (SFCE) Malignant Mesenchymal Tumor (MMT) Committee and the French Sarcoma Group (GSF-GETO).
PMID 42735453 — rhabdomyosarcoma, neoplasms, drug therapy, sarcoma, aged, adolescent, therapeutics, prognosis, chemotherapy		ESMO Open20260
Deni Study: Real-World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group.
PMID 42522292 — fibromatosis, aggressive, pain, neoplasms, sarcoma, fatigue, drug tapering, therapeutics		Int J Cancer20260
MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.
PMID 42331846 — genes, microscopy, electron, scanning transmission, perivascular epithelioid cell neoplasms, neoplasms, classification, therapeutics, mutation		Nat Commun20260
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PMID 42334926 — neoplasms, drug therapy, sarcoma, chemotherapy, adjuvant, chemotherapy		J Med Econ20260
Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.
PMID 42291149 — registries, cohort studies, drug therapy, sarcoma, chemotherapy, adjuvant, work, therapeutics, tissues, aids-related complex, chemotherapy		EClinicalMedicine20260

Clinical Studies 39

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Chair: 2

By phase:

Phase 2 16
N/A 8
Phase 3 7
Phase 1 4
Phase 1/Phase 2 4

By status:

Completed 19
Recruiting 14
Unknown 3
Active not recruiting 2
Terminated 1

By type:

Interventional 35
Observational 4

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 3
multicentric5to9 8
multicentricup10 22

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma 202)
2025-523997-18-00 — safety, sarcoma, therapeutics		Phase 1/Phase 2Recruiting2026
INTER EWING 1 International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma Trial 1
2024-511989-36-00 — radiotherapy, sarcoma, ewing, biomedical research, drug therapy, sarcoma, research, chemotherapy		Phase 3Recruiting2025
Public Title Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First line Treatment in Participants with Metastatic Leiomyosarcoma
2022-502975-45-00 — leiomyosarcoma, doxorubicin, therapeutics		Phase 3Active not recruiting2023
Interest of post operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high risk of relapse based on a biologic test performed on the tumor
2023-506350-21-00 — leiomyosarcoma, neoplasms, classification, drug therapy, chemotherapy, adjuvant, chemotherapy		Phase 2Recruiting2025
Interest of Post operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
NCT06524583 — leiomyosarcoma, uterus, doxorubicin, drug therapy, chemotherapy, adjuvant, trabectedin, chemotherapy		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS